BP Equities Q3FY26 Result Update GHCL Ltd.
BP Wealth
...
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
RESEARCH REPORTS ALERTS
Load latest
Google or static link led you to an intermediate page.
- All Recent
- Upside
- Buy
- Sell
- Recent Upgrades
- Recent Downgrades
- IPO
- Sector Updates
- Most Recent
- Top Upside
Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jan 2026 | GHCL |
BP Wealth
|
455.30 | 530.70 (-14.21%) |
Results Update
|
||||||
| 30 Jan 2026 | ASK Automotive |
BP Wealth
|
455.80 | 445.95 (2.21%) |
Results Update
|
||||||
| 30 Jan 2026 | Dabur |
BP Wealth
|
452.80 | 506.60 (-10.62%) |
Results Update
|
||||||
| 29 Jan 2026 | Maruti Suzuki |
BP Wealth
|
12956.00 | 14502.00 (-10.66%) |
Results Update
|
||||||
| 29 Jan 2026 | Manorama Industries |
BP Wealth
|
1371.40 | 1375.80 (-0.32%) |
Results Update
|
||||||
| 28 Jan 2026 | Marico |
BP Wealth
|
831.45 | 736.65 (12.87%) |
Results Update
|
||||||
| 27 Jan 2026 | UltraTech Cement |
BP Wealth
|
11368.00 | 12589.00 (-9.70%) |
Results Update
|
||||||
| 25 Jan 2026 | Gujarat Themis |
BP Wealth
|
356.25 | 367.00 | 315.65 (12.86%) | Target met |
Buy
|
Gujarat Themis Biosyn Limited Tgt 367
BP Wealth
Gujarat Themis Biosyn Limited (GTBL), incorporated in 1981, is an Indian pharmaceutical company specialising in the manufacturing of fermentation-based pharmaceutical intermediates and APIs. The company focuses on niche and critical intermediates, primarily Rifamycin S and Rifamycin O, which are key inputs for Rifampicin and Rifaximin antibiotics widely used in the treatment of tuberculosis and bacterial infections. GTBL operates state-of-the-art fermentation facilities at Vapi with an expanded installed capacity of ~990 KL, enabling scalable production with high cost efficiency, consistent quality, and operational flexibility across multiple fermentation products. The niche nature of Rifamycin intermediates used in critical therapies such as tuberculosis ensures stable demand and strategic importance. Additionally, the company's ongoing investments in R&D, new molecule development, and forward integration into APIs further reinforce its positioning by deepening technical complexity and customer stickiness. The company previously considered a merger with Themis...
|
|||
| 24 Jan 2026 | Godrej Consumer Products |
BP Wealth
|
1022.00 | 1240.40 (-17.61%) |
Results Update
|
||||||
| 22 Jan 2026 | Dalmia Bharat |
BP Wealth
|
1713.80 | 2143.70 (-20.05%) |
Results Update
|
||||||
|
more
loading
|
|||||||||||
* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.